{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:26:56Z","timestamp":1791581216727,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna Therapeutics","doi-asserted-by":"publisher","award":["OA22BEA4"],"award-info":[{"award-number":["OA22BEA4"]}],"id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R21 AI136556"],"award-info":[{"award-number":["5R21 AI136556"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>MF59-adjuvanted gB subunit (gB\/MF59) vaccine demonstrated approximately 50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting that efforts to improve this vaccine design might yield a vaccine suitable for licensure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A messenger RNA (mRNA)\u2013based vaccine candidate encoding HCMV gB and pentameric complex (PC), mRNA-1647, is currently in late-stage efficacy trials. However, its immunogenicity has not been compared to the partially effective gB\/MF59 vaccine. We assessed neutralizing and Fc-mediated immunoglobulin G (IgG) effector antibody responses induced by mRNA-1647 in both HCMV-seropositive and -seronegative vaccinees from a first-in-human clinical trial through 1 year following third vaccination using a systems serology approach. Furthermore, we compared peak anti-gB antibody responses in seronegative mRNA-1647 vaccinees to that of seronegative gB\/MF59 vaccine recipients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>mRNA-1647 vaccination elicited and boosted HCMV-specific IgG responses in seronegative and seropositive vaccinees, respectively, including neutralizing and Fc-mediated effector antibody responses. gB-specific IgG responses were lower than PC-specific IgG responses. gB-specific IgG and antibody-dependent cellular phagocytosis responses were lower than those elicited by gB\/MF59. However, mRNA-1647 elicited higher neutralization and antibody-dependent cellular cytotoxicity (ADCC) responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, mRNA-1647 vaccination induced polyfunctional and durable HCMV-specific antibody responses, with lower gB-specific IgG responses but higher neutralization and ADCC responses compared to the gB\/MF59 vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03382405 (mRNA-1647) and NCT00133497 (gB\/MF59).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad593","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T22:08:13Z","timestamp":1707343693000},"page":"455-466","source":"Crossref","is-referenced-by-count":81,"title":["Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB\/MF59 Vaccine"],"prefix":"10.1093","volume":"230","author":[{"given":"Xintao","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-6688","authenticated-orcid":false,"given":"Krithika P","family":"Karthigeyan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-3769","authenticated-orcid":false,"given":"Savannah","family":"Herbek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Valencia","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-5615","authenticated-orcid":false,"given":"Jennifer A","family":"Jenks","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Webster","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9199-8985","authenticated-orcid":false,"given":"Itzayana G","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pollara","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Andy","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M","family":"Gerber","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B","family":"Walter","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati , Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hou","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Koch","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[{"name":"Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie R","family":"Permar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024081523522281500_jiad593-B1","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/cid\/cit629","article-title":"Congenital cytomegalovirus infection: clinical outcome","volume":"57","author":"Boppana","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024081523522281500_jiad593-B2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/jcp.54.2.84","article-title":"Investigation of CMV disease in immunocompromised patients","volume":"54","author":"Emery","year":"2001","journal-title":"J Clin Pathol"},{"key":"2024081523522281500_jiad593-B3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-virology-100220-010653","article-title":"Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development","volume":"9","author":"Hu","year":"2022","journal-title":"Annu Rev Virol"},{"key":"2024081523522281500_jiad593-B4","doi-asserted-by":"crossref","first-page":"e00268-17","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2024081523522281500_jiad593-B5","first-page":"v","article-title":"Human cytomegalovirus. Preface","volume":"325","author":"Shenk","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"2024081523522281500_jiad593-B6","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J Virol"},{"key":"2024081523522281500_jiad593-B7","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024081523522281500_jiad593-B8","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","article-title":"Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease","volume":"221","author":"Nelson","year":"2020","journal-title":"J Infect Dis"},{"key":"2024081523522281500_jiad593-B9","doi-asserted-by":"crossref","first-page":"eabb3611","DOI":"10.1126\/scitranslmed.abb3611","article-title":"Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans","volume":"12","author":"Jenks","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024081523522281500_jiad593-B10","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.vaccine.2022.07.026","article-title":"Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level","volume":"40","author":"Byrne","year":"2022","journal-title":"Vaccine"},{"key":"2024081523522281500_jiad593-B11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2024081523522281500_jiad593-B12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2024081523522281500_jiad593-B13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/infdis\/jiac341","article-title":"Characterization of plasma immunoglobulin G responses in elite neutralizers of human cytomegalovirus","volume":"226","author":"Harnois","year":"2022","journal-title":"J Infect Dis"},{"key":"2024081523522281500_jiad593-B14","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024081523522281500_jiad593-B15","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024081523522281500_jiad593-B16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/vaccines7040129","article-title":"Impact of maternal immunity on congenital cytomegalovirus birth prevalence and infant outcomes: a systematic review","volume":"7","author":"Coppola","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"2024081523522281500_jiad593-B17","doi-asserted-by":"crossref","first-page":"e156827","DOI":"10.1172\/JCI156827","article-title":"Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection","volume":"132","author":"Semmes","year":"2022","journal-title":"J Clin Invest"},{"key":"2024081523522281500_jiad593-B18","doi-asserted-by":"crossref","first-page":"e167768","DOI":"10.1172\/jci.insight.167768","article-title":"ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission","volume":"8","author":"Semmes","year":"2023","journal-title":"JCI Insight"},{"key":"2024081523522281500_jiad593-B19","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2024081523522281500_jiad593-B20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"2024081523522281500_jiad593-B21","author":"Ciaramella"},{"key":"2024081523522281500_jiad593-B22","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1128\/JVI.79.16.10330-10338.2005","article-title":"Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"2024081523522281500_jiad593-B23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-023-36683-x","article-title":"The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread","volume":"14","author":"Gomes","year":"2023","journal-title":"Nat Commun"},{"key":"2024081523522281500_jiad593-B24","doi-asserted-by":"crossref","first-page":"913215","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Co\u00ebnon","year":"2022","journal-title":"Front Immunol"},{"key":"2024081523522281500_jiad593-B25","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"2024081523522281500_jiad593-B26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"2024081523522281500_jiad593-B27","doi-asserted-by":"crossref","first-page":"107624","DOI":"10.1016\/j.celrep.2020.107624","article-title":"Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge","volume":"31","author":"Felber","year":"2020","journal-title":"Cell Rep"},{"key":"2024081523522281500_jiad593-B28","doi-asserted-by":"publisher","article-title":"The pentameric complex is not required for vertical transmission of cytomegalovirus in seronegative pregnant rhesus macaques","author":"Wang","DOI":"10.1101\/2023.06.15.545169"},{"key":"2024081523522281500_jiad593-B29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2024081523522281500_jiad593-B30","doi-asserted-by":"crossref","first-page":"e139296","DOI":"10.1172\/JCI139296","article-title":"Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus","volume":"131","author":"Vlahava","year":"2021","journal-title":"J Clin Invest"},{"key":"2024081523522281500_jiad593-B31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"2024081523522281500_jiad593-B32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2020.07.013","article-title":"Cytomegalovirus as an immunomodulator across the lifespan","volume":"44","author":"Semmes","year":"2020","journal-title":"Curr Opin Virol"},{"key":"2024081523522281500_jiad593-B33","doi-asserted-by":"crossref","first-page":"e00186-20","DOI":"10.1128\/JVI.00186-20","article-title":"Human cytomegalovirus glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunization","volume":"94","author":"Nelson","year":"2020","journal-title":"J Virol"},{"key":"2024081523522281500_jiad593-B34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"2024081523522281500_jiad593-B35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"2024081523522281500_jiad593-B36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14728222.2021.1907343","article-title":"Targeting Fc effector function in vaccine design","volume":"25","author":"Richardson","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"2024081523522281500_jiad593-B37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad593\/56576608\/jiad593.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/455\/58808678\/jiad593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/455\/58808678\/jiad593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T23:53:46Z","timestamp":1723766026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/2\/455\/7600044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad593","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,15]]},"published":{"date-parts":[[2024,2,7]]}}}